Hepion Closes Gravitas Acquisition, Gains FDA-Endorsed Opioid Countermeasure
HEPA is trading near its 52-week low of $0.31 (80% below the low).
Summary
Hepion completed its acquisition of Gravitas Life Sciences on October 6, adding GV104, a clinical-stage opioid countermeasure with an active IND and a 505(b)(2) pathway, plus GV023, an oral anti-TNF antibody. The FDA has stated additional clinical studies are not needed to define GV104's dosing window, shifting the critical path to manufacturing. Leadership changed on October 9: Dr. Appajosyula became CEO and Gary Stetz moved to CFO. The company now has three programs and plans to advance GV104 CMC and registration batches in 2027, seek GV023 regulatory guidance, and develop its circulating tumor RNA diagnostic as a laboratory-developed test. This transforms Hepion from a cash-strapped, delisted shell into a multi-asset biotech with a near-term regulatory path.
At the time of this announcement, HEPA was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $0.31 to $0.42. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.